- Free from Publisher J Rosenstock, D Sugimoto, P Strange, JA … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—A1C improvements from baseline were similar in both groups (−1.7 vs.
−1.5% for insulin glargine vs. rosiglitazone, respectively); however, when
baseline A1C was >9.5%, the reduction of A1C with insulin glargine was ... Cited by 100 - Related articles - BL Direct - All 8 versions
K Aljabri, SE Kozak, DM Thompson - The American journal of medicine, 2004 - Elsevier We conducted a nonblinded, open-label, randomized controlled trial involving 62
patients with type 2 diabetes and glycosylated hemoglobin (HbA 1C ) levels
>8.0%. Patients received either pioglitazone or bedtime NPH insulin in ... Cited by 62 - Related articles - All 3 versions
GE Dailey, MA Noor, JS Park, S Bruce, FT … - The American journal of medicine, 2004 - Elsevier Following an open-label, lead-in phase to optimize the dosing of
glyburide/metformin tablets, 365 patients randomly received additive therapy
comprising rosiglitazone (4 mg once daily) or placebo for 24 weeks. Based ... Cited by 63 - Related articles - All 9 versions
H Yki-Järvinen, R Kauppinen-Mäkelin, M … - Diabetologia, 2006 - Springer Page 1. Diabetologia (2006) 49: 442–451 DOI 10.1007/s00125-005-0132-0 ARTICLE H.
Yki-Järvinen . R. Kauppinen-Mäkelin . M. Tiikkainen . M. Vähätalo . ... Cited by 156 - Related articles - BL Direct - All 7 versions
AI Vinik, Q Zhang - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—HRQOL was evaluated in 217 subjects uncontrolled
with sulfonylurea plus metformin, enrolled in a 24-week, multicenter,
randomized, open-label, parallel-group trial of add-on insulin glargine ... Cited by 24 - Related articles - BL Direct - All 7 versions
- Free from Publisher C Triplitt, L Glass, Y Miyazaki, E Wajcberg, A … - Diabetes care, 2006 - Am Diabetes Assoc RESULTS—A1C and FPG decreased similarly in the glargine insulin (9.1 ± 0.4 to
7.6 ± 0.3% and 212 ± 14 to 139 ± 5 mg/dl, respectively, both P < 0.0001) and
rosiglitazone (9.4 ± 0.3 to 7.6 ± 0.4% and 223 ± 14 to 160 ± 19 mg/dl, ... Cited by 9 - Related articles - BL Direct - All 6 versions
HU Janka, G Plewe, MC Riddle, C Kliebe- … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a 24-week, multinational, multicenter, open,
parallel group clinical trial, 371 insulin-naïve patients with poor glycemic
control (fasting blood glucose [FBG] ≥120 mg/dl, HbA 1c 7.5–10.5%) on ... Cited by 222 - Related articles - All 8 versions
HC Gerstein, JF Yale, SB Harris, M Issa, JA … - DIABETIC MEDICINE-CHICHESTER-, 2006 - interscience.wiley.com Methods Consenting adults aged 18–80 years with Type 2 diabetes for at least 6
months, HbA 1c of 7.5–11%, and on 0, 1 or 2 oral agents, were randomized to
one of two therapeutic approaches for 24 weeks: evening insulin glargine ... Cited by 31 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org M Davies, F Storms, S Shutler, M Bianchi- … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—At baseline, mean diabetes duration was 12.3 ± 7.2 years, and 72% of
subjects were pretreated with insulin. At end point, there was no significant
difference in the incidence of severe hypoglycemia between algorithms 1 and ... Cited by 65 - Related articles - All 10 versions
AN Goudswaard, NJ Furlong, GE Rutten, RP … - Cochrane Database Syst Rev, 2004 - igitur-archive.library.uu.nl This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
Collaboration and published in The Cochrane Library 2006, Issue 2 ... Insulin
monotherapy versus combinations of insulin with oral hypoglycaemic agents ... Cited by 42 - Related articles - View as HTML - All 8 versions
